$LLY - ELI LILLY’S NEW OBESITY DRUG DELIVERS 23.3% WEIGHT LOSS

ELI LILLY’S EXPERIMENTAL DRUG ELORALINTIDE, COMBINED WITH ZEPBOUND, DELIVERED 23.3% AVERAGE WEIGHT LOSS OVER ROUGHLY 11 MONTHS, COMPARED WITH 14.8% FOR ZEPBOUND ALONE IN PATIENTS WITH TYPE 2 DIABETES.

HOWEVER, 11–27% DISCONTINUED THE COMBINATION DUE TO SIDE EFFECTS, HIGHLIGHTING TOLERABILITY CONCERNS.

LILLY PLANS TO ADVANCE THE TREATMENT INTO LATE-STAGE TRIALS LATER THIS YEAR. ...